世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
予兆検査 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030Predictive Presymptomatic Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 予測的無症候性検査の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％CAGRで2030年までに100万米ドルの再調整された規模になると予測されています。 予測的無症候性... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー予測的無症候性検査の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％CAGRで2030年までに100万米ドルの再調整された規模になると予測されています。予測的無症候性検査の北米市場は、2023年に100万米ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万米ドルに達すると予測されています。 無症候性予測検査のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 無症候性予測検査のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 症候性予測検査の世界の主要企業には、23andMe, Inc.、Abbott Laboratories、Bayer HealthCare AG、Biocartis SA、BioHelix Corporation、bioMerieux S.A.、Celera Corporation（Quest Diagnostics）、Cepheid（Danaher）、Daan Diagnostics Ltd.などが含まれる。2023年、世界の大手5社の売上高シェアは約 %である。 レポートの範囲 本レポートは、地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当て、予測的無症候性検査の世界市場を包括的に提示することを目的としています。 予測的無症候性検査市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供しています。定量的、定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、Predictive Presymptomatic Testingに関する情報に基づいたビジネス上の意思決定を行うことを支援します。 市場区分 企業別 23andMe, Inc. アボット・ラボラトリーズ バイエルヘルスケアAG バイオカルティスSA バイオヘリックス・コーポレーション バイオメリューS.A. セレラ・コーポレーション（クエスト・ダイアグノスティックス） セファイド（ダナハー） ダーン・ダイアグノスティックス EKF ダイアグノスティックス・ホールディングス plc タイプ別セグメント 分子検査 細胞遺伝学的検査 生化学検査 アプリケーション別セグメント 乳がんおよび卵巣がん 大腸がん アルツハイマー病 多発性内分泌腫瘍2型 血色素症 地域別 北米 米国 カナダ ヨーロッパ ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章：報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：予兆検査メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。 第3章：タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性を網羅し、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのに役立ちます。 第4章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章：地域レベルでの予兆予測検査の収益。各地域の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場スペース、市場規模を紹介しています。 第6章：国別予測前症候群検査の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Predictive Presymptomatic Testing Product Introduction 1.2 Global Predictive Presymptomatic Testing Market Size Forecast 1.3 Predictive Presymptomatic Testing Market Trends & Drivers 1.3.1 Predictive Presymptomatic Testing Industry Trends 1.3.2 Predictive Presymptomatic Testing Market Drivers & Opportunity 1.3.3 Predictive Presymptomatic Testing Market Challenges 1.3.4 Predictive Presymptomatic Testing Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Predictive Presymptomatic Testing Players Revenue Ranking (2023) 2.2 Global Predictive Presymptomatic Testing Revenue by Company (2019-2024) 2.3 Key Companies Predictive Presymptomatic Testing Manufacturing Base Distribution and Headquarters 2.4 Key Companies Predictive Presymptomatic Testing Product Offered 2.5 Key Companies Time to Begin Mass Production of Predictive Presymptomatic Testing 2.6 Predictive Presymptomatic Testing Market Competitive Analysis 2.6.1 Predictive Presymptomatic Testing Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Predictive Presymptomatic Testing Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Predictive Presymptomatic Testing as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Molecular Testing 3.1.2 Cytogenic Testing 3.1.3 Biochemical Testing 3.2 Global Predictive Presymptomatic Testing Sales Value by Type 3.2.1 Global Predictive Presymptomatic Testing Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Predictive Presymptomatic Testing Sales Value, by Type (2019-2030) 3.2.3 Global Predictive Presymptomatic Testing Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Breast and Ovarian Cancer 4.1.2 Colorectal Cancer 4.1.3 Alzheimer's Disease 4.1.4 Multiple Endocrine Neoplasia Type 2 4.1.5 Haemochromatosis 4.2 Global Predictive Presymptomatic Testing Sales Value by Application 4.2.1 Global Predictive Presymptomatic Testing Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Predictive Presymptomatic Testing Sales Value, by Application (2019-2030) 4.2.3 Global Predictive Presymptomatic Testing Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Predictive Presymptomatic Testing Sales Value by Region 5.1.1 Global Predictive Presymptomatic Testing Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Predictive Presymptomatic Testing Sales Value by Region (2019-2024) 5.1.3 Global Predictive Presymptomatic Testing Sales Value by Region (2025-2030) 5.1.4 Global Predictive Presymptomatic Testing Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Predictive Presymptomatic Testing Sales Value, 2019-2030 5.2.2 North America Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Predictive Presymptomatic Testing Sales Value, 2019-2030 5.3.2 Europe Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Predictive Presymptomatic Testing Sales Value, 2019-2030 5.4.2 Asia Pacific Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Predictive Presymptomatic Testing Sales Value, 2019-2030 5.5.2 South America Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Predictive Presymptomatic Testing Sales Value, 2019-2030 5.6.2 Middle East & Africa Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Predictive Presymptomatic Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Predictive Presymptomatic Testing Sales Value 6.3 United States 6.3.1 United States Predictive Presymptomatic Testing Sales Value, 2019-2030 6.3.2 United States Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Predictive Presymptomatic Testing Sales Value, 2019-2030 6.4.2 Europe Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Predictive Presymptomatic Testing Sales Value, 2019-2030 6.5.2 China Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.5.3 China Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Predictive Presymptomatic Testing Sales Value, 2019-2030 6.6.2 Japan Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Predictive Presymptomatic Testing Sales Value, 2019-2030 6.7.2 South Korea Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Predictive Presymptomatic Testing Sales Value, 2019-2030 6.8.2 Southeast Asia Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Predictive Presymptomatic Testing Sales Value, 2019-2030 6.9.2 India Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.9.3 India Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 23andMe, Inc. 7.1.1 23andMe, Inc. Profile 7.1.2 23andMe, Inc. Main Business 7.1.3 23andMe, Inc. Predictive Presymptomatic Testing Products, Services and Solutions 7.1.4 23andMe, Inc. Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.1.5 23andMe, Inc. Recent Developments 7.2 Abbott Laboratories 7.2.1 Abbott Laboratories Profile 7.2.2 Abbott Laboratories Main Business 7.2.3 Abbott Laboratories Predictive Presymptomatic Testing Products, Services and Solutions 7.2.4 Abbott Laboratories Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.2.5 Abbott Laboratories Recent Developments 7.3 Bayer HealthCare AG 7.3.1 Bayer HealthCare AG Profile 7.3.2 Bayer HealthCare AG Main Business 7.3.3 Bayer HealthCare AG Predictive Presymptomatic Testing Products, Services and Solutions 7.3.4 Bayer HealthCare AG Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.3.5 Biocartis SA Recent Developments 7.4 Biocartis SA 7.4.1 Biocartis SA Profile 7.4.2 Biocartis SA Main Business 7.4.3 Biocartis SA Predictive Presymptomatic Testing Products, Services and Solutions 7.4.4 Biocartis SA Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.4.5 Biocartis SA Recent Developments 7.5 BioHelix Corporation 7.5.1 BioHelix Corporation Profile 7.5.2 BioHelix Corporation Main Business 7.5.3 BioHelix Corporation Predictive Presymptomatic Testing Products, Services and Solutions 7.5.4 BioHelix Corporation Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.5.5 BioHelix Corporation Recent Developments 7.6 bioMerieux S.A. 7.6.1 bioMerieux S.A. Profile 7.6.2 bioMerieux S.A. Main Business 7.6.3 bioMerieux S.A. Predictive Presymptomatic Testing Products, Services and Solutions 7.6.4 bioMerieux S.A. Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.6.5 bioMerieux S.A. Recent Developments 7.7 Celera Corporation (Quest Diagnostics) 7.7.1 Celera Corporation (Quest Diagnostics) Profile 7.7.2 Celera Corporation (Quest Diagnostics) Main Business 7.7.3 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Products, Services and Solutions 7.7.4 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.7.5 Celera Corporation (Quest Diagnostics) Recent Developments 7.8 Cepheid (Danaher) 7.8.1 Cepheid (Danaher) Profile 7.8.2 Cepheid (Danaher) Main Business 7.8.3 Cepheid (Danaher) Predictive Presymptomatic Testing Products, Services and Solutions 7.8.4 Cepheid (Danaher) Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.8.5 Cepheid (Danaher) Recent Developments 7.9 Daan Diagnostics Ltd. 7.9.1 Daan Diagnostics Ltd. Profile 7.9.2 Daan Diagnostics Ltd. Main Business 7.9.3 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Products, Services and Solutions 7.9.4 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.9.5 Daan Diagnostics Ltd. Recent Developments 7.10 EKF Diagnostics Holdings plc 7.10.1 EKF Diagnostics Holdings plc Profile 7.10.2 EKF Diagnostics Holdings plc Main Business 7.10.3 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Products, Services and Solutions 7.10.4 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.10.5 EKF Diagnostics Holdings plc Recent Developments 8 Industry Chain Analysis 8.1 Predictive Presymptomatic Testing Industrial Chain 8.2 Predictive Presymptomatic Testing Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Predictive Presymptomatic Testing Sales Model 8.5.2 Sales Channel 8.5.3 Predictive Presymptomatic Testing Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Predictive Presymptomatic Testing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Predictive Presymptomatic Testing Product Introduction 1.2 Global Predictive Presymptomatic Testing Market Size Forecast 1.3 Predictive Presymptomatic Testing Market Trends & Drivers 1.3.1 Predictive Presymptomatic Testing Industry Trends 1.3.2 Predictive Presymptomatic Testing Market Drivers & Opportunity 1.3.3 Predictive Presymptomatic Testing Market Challenges 1.3.4 Predictive Presymptomatic Testing Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Predictive Presymptomatic Testing Players Revenue Ranking (2023) 2.2 Global Predictive Presymptomatic Testing Revenue by Company (2019-2024) 2.3 Key Companies Predictive Presymptomatic Testing Manufacturing Base Distribution and Headquarters 2.4 Key Companies Predictive Presymptomatic Testing Product Offered 2.5 Key Companies Time to Begin Mass Production of Predictive Presymptomatic Testing 2.6 Predictive Presymptomatic Testing Market Competitive Analysis 2.6.1 Predictive Presymptomatic Testing Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Predictive Presymptomatic Testing Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Predictive Presymptomatic Testing as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Molecular Testing 3.1.2 Cytogenic Testing 3.1.3 Biochemical Testing 3.2 Global Predictive Presymptomatic Testing Sales Value by Type 3.2.1 Global Predictive Presymptomatic Testing Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Predictive Presymptomatic Testing Sales Value, by Type (2019-2030) 3.2.3 Global Predictive Presymptomatic Testing Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Breast and Ovarian Cancer 4.1.2 Colorectal Cancer 4.1.3 Alzheimer's Disease 4.1.4 Multiple Endocrine Neoplasia Type 2 4.1.5 Haemochromatosis 4.2 Global Predictive Presymptomatic Testing Sales Value by Application 4.2.1 Global Predictive Presymptomatic Testing Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Predictive Presymptomatic Testing Sales Value, by Application (2019-2030) 4.2.3 Global Predictive Presymptomatic Testing Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Predictive Presymptomatic Testing Sales Value by Region 5.1.1 Global Predictive Presymptomatic Testing Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Predictive Presymptomatic Testing Sales Value by Region (2019-2024) 5.1.3 Global Predictive Presymptomatic Testing Sales Value by Region (2025-2030) 5.1.4 Global Predictive Presymptomatic Testing Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Predictive Presymptomatic Testing Sales Value, 2019-2030 5.2.2 North America Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Predictive Presymptomatic Testing Sales Value, 2019-2030 5.3.2 Europe Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Predictive Presymptomatic Testing Sales Value, 2019-2030 5.4.2 Asia Pacific Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Predictive Presymptomatic Testing Sales Value, 2019-2030 5.5.2 South America Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Predictive Presymptomatic Testing Sales Value, 2019-2030 5.6.2 Middle East & Africa Predictive Presymptomatic Testing Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Predictive Presymptomatic Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Predictive Presymptomatic Testing Sales Value 6.3 United States 6.3.1 United States Predictive Presymptomatic Testing Sales Value, 2019-2030 6.3.2 United States Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Predictive Presymptomatic Testing Sales Value, 2019-2030 6.4.2 Europe Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Predictive Presymptomatic Testing Sales Value, 2019-2030 6.5.2 China Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.5.3 China Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Predictive Presymptomatic Testing Sales Value, 2019-2030 6.6.2 Japan Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Predictive Presymptomatic Testing Sales Value, 2019-2030 6.7.2 South Korea Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Predictive Presymptomatic Testing Sales Value, 2019-2030 6.8.2 Southeast Asia Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Predictive Presymptomatic Testing Sales Value, 2019-2030 6.9.2 India Predictive Presymptomatic Testing Sales Value by Type (%), 2023 VS 2030 6.9.3 India Predictive Presymptomatic Testing Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 23andMe, Inc. 7.1.1 23andMe, Inc. Profile 7.1.2 23andMe, Inc. Main Business 7.1.3 23andMe, Inc. Predictive Presymptomatic Testing Products, Services and Solutions 7.1.4 23andMe, Inc. Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.1.5 23andMe, Inc. Recent Developments 7.2 Abbott Laboratories 7.2.1 Abbott Laboratories Profile 7.2.2 Abbott Laboratories Main Business 7.2.3 Abbott Laboratories Predictive Presymptomatic Testing Products, Services and Solutions 7.2.4 Abbott Laboratories Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.2.5 Abbott Laboratories Recent Developments 7.3 Bayer HealthCare AG 7.3.1 Bayer HealthCare AG Profile 7.3.2 Bayer HealthCare AG Main Business 7.3.3 Bayer HealthCare AG Predictive Presymptomatic Testing Products, Services and Solutions 7.3.4 Bayer HealthCare AG Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.3.5 Biocartis SA Recent Developments 7.4 Biocartis SA 7.4.1 Biocartis SA Profile 7.4.2 Biocartis SA Main Business 7.4.3 Biocartis SA Predictive Presymptomatic Testing Products, Services and Solutions 7.4.4 Biocartis SA Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.4.5 Biocartis SA Recent Developments 7.5 BioHelix Corporation 7.5.1 BioHelix Corporation Profile 7.5.2 BioHelix Corporation Main Business 7.5.3 BioHelix Corporation Predictive Presymptomatic Testing Products, Services and Solutions 7.5.4 BioHelix Corporation Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.5.5 BioHelix Corporation Recent Developments 7.6 bioMerieux S.A. 7.6.1 bioMerieux S.A. Profile 7.6.2 bioMerieux S.A. Main Business 7.6.3 bioMerieux S.A. Predictive Presymptomatic Testing Products, Services and Solutions 7.6.4 bioMerieux S.A. Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.6.5 bioMerieux S.A. Recent Developments 7.7 Celera Corporation (Quest Diagnostics) 7.7.1 Celera Corporation (Quest Diagnostics) Profile 7.7.2 Celera Corporation (Quest Diagnostics) Main Business 7.7.3 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Products, Services and Solutions 7.7.4 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.7.5 Celera Corporation (Quest Diagnostics) Recent Developments 7.8 Cepheid (Danaher) 7.8.1 Cepheid (Danaher) Profile 7.8.2 Cepheid (Danaher) Main Business 7.8.3 Cepheid (Danaher) Predictive Presymptomatic Testing Products, Services and Solutions 7.8.4 Cepheid (Danaher) Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.8.5 Cepheid (Danaher) Recent Developments 7.9 Daan Diagnostics Ltd. 7.9.1 Daan Diagnostics Ltd. Profile 7.9.2 Daan Diagnostics Ltd. Main Business 7.9.3 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Products, Services and Solutions 7.9.4 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.9.5 Daan Diagnostics Ltd. Recent Developments 7.10 EKF Diagnostics Holdings plc 7.10.1 EKF Diagnostics Holdings plc Profile 7.10.2 EKF Diagnostics Holdings plc Main Business 7.10.3 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Products, Services and Solutions 7.10.4 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Revenue (US$ Million) & (2019-2024) 7.10.5 EKF Diagnostics Holdings plc Recent Developments 8 Industry Chain Analysis 8.1 Predictive Presymptomatic Testing Industrial Chain 8.2 Predictive Presymptomatic Testing Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Predictive Presymptomatic Testing Sales Model 8.5.2 Sales Channel 8.5.3 Predictive Presymptomatic Testing Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
QYResearch 社の最新刊レポート本レポートと同じKEY WORD（demand）の最新刊レポートよくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/07/05 10:26 162.17 円 175.82 円 209.73 円 |
